Multiple Sclerosis Research
The mission of the Program in Multiple Sclerosis is to provide the best possible treatment for individuals and their family members suffering from multiple sclerosis (MS) and to educate the community and community based physicians in the recognition and care of patients with MS. We also strive to further knowledge in MS and its treatment through basic and clinical research.
Current Faculty Members Involved in Research:
Emily Pharr, MD
CURRENT CLINICAL TRIALS
2013-Present: ASSESS-A study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg with glatiramer acetate 20 mg in patients with relapsing-remitting MS, Sponsor: Novartis Pharmaceuticals Corporation
2013-Present: CONCERTO-A study to evaluate the efficacy, safety and tolerability of 2 doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in patients with relapsing-remitting MS, Sponsor: Teva Pharmaceutical Industries Limited
Contact Information: Janet Hutchens, BS, CCRC, firstname.lastname@example.org, (336) 716-1715